News | June 06, 2022
ANI Pharmaceuticals consolidates operation post Novitium acquisition
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
This cost-effective tool will be of immense benefit to other high burden countries as well.
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
All the capex is being met through internal accruals only
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Subscribe To Our Newsletter & Stay Updated
